NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Neuropharmacology

• Publication date

  2004-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.NEUROPHARM.2004.03.011PMID 15223297
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Striatal glutamatergic mechanisms and extrapyramidal movement disorders

  2009cited by this paper
• Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa‐induced response alterations in unilateral nigrostriatal 6‐OHDA lesioned rats

  2003cited by this paper
• Phosphorylation of the AMPA receptor GluR1 subunit is required for synaptic plasticity and retention of spatial memory.

  2003cited by this paper
• Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats.

  2003cited by this paper
• Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: Intrastriatal microinjection studies in the 6‐OHDA‐lesioned rat

  2002cited by this paper
• Reversible inhibition of CREB/ATF transcription factors in region CA1 of the dorsal hippocampus disrupts hippocampus-dependent spatial memory.

  2002cited by this paper
• Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.

  2002cited by this paper
• Expression of constitutively active CREB protein facilitates the late phase of long-term potentiation by enhancing synaptic capture.

  2002cited by this paper
• Sequence determinants on the NR2A and NR2B subunits of NMDA receptor responsible for specificity of phosphorylation by CaMKII.

  2002cited by this paper
• The role of PKA, CaMKII, and PKC in avoidance conditioning: permissive or instructive?

  2002cited by this paper
• Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease

  2002cited by this paper
• PKC activation rescues LTP from NMDA receptor blockade

  2001cited by this paper
• Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study

  2001cited by this paper
• Calmodulin Kinase II Attenuation of Gene Transcription by Preventing cAMP Response Element-binding Protein (CREB) Dimerization and Binding of the CREB-binding Protein*

  2001cited by this paper
• Cellular Signaling through Multifunctional Ca2+/Calmodulin-dependent Protein Kinase II*

  2001cited by this paper
• Dopamine D1 Receptor-Dependent Trafficking of Striatal NMDA Glutamate Receptors to the Postsynaptic Membrane

  2001cited by this paper
• Dopaminergic control of synaptic plasticity in the dorsal striatum

  2001cited by this paper
• Potassium chloride depolarization mediates CREB phosphorylation in striatal neurons in an NMDA receptor-dependent manner.

  2001cited by this paper
• Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.

  2000cited by this paper
• Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism.

  2000cited by this paper
• AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys

  2000cited by this paper
• Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.

  2000cited by this paper
• Non‐NMDA receptor‐mediated mechanisms are involved in levodopa‐induced motor response alterations in parkinsonian rats

  2000cited by this paper
• CP-101606 Pfizer Inc.

  2000cited by this paper
• CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents.

  2000cited by this paper
• Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.

  2000cited by this paper
• Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.

  2000cited by this paper
• Tyrosine phosphorylation modulates the interaction of calmodulin with its target proteins.

  1999cited by this paper
• Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment.

  1999cited by this paper
• Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits.

  1999cited by this paper
• Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.

  1999cited by this paper
• Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.

  1999cited by this paper
• Classification of fluctuations in patients with Parkinson's disease

  1998cited by this paper
• Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration.

  1998cited by this paper
• A trial of dextromethorphan in parkinsonian patients with motor response complications

  1998cited by this paper
• CP-101,606: An NR2B-Selective NMDA Receptor Antagonist.

  1998cited by this paper
• Amantadine reduces levodopa‐induced dyskinesias in parkinsonian monkeys

  1998cited by this paper
• Motor Complications of Chronic Levodopa Therapy in Parkinson's Disease

  1997cited by this paper
• Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat.

  1997cited by this paper
• NMDA Receptor and the Tyrosine Phosphorylation of Its 2B Subunit in Taste Learning in the Rat Insular Cortex

  1997cited by this paper
• Cellular distribution of the NMDA receptor NR2A/2B subunits in the rat striatum.

  1996cited by this paper
• Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade.

  1995cited by this paper
• Structure and function of the NMDA receptor channel.

  1995cited by this paper
• NMDA receptor blockade reverses motor response alterations induced by levodopa.

  1994cited by this paper
• Organization of N‐methyl‐D‐aspartate glutamate receptor gene expression in the basal ganglia of the rat

  1994cited by this paper
• Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration.

  1994cited by this paper
• A Clinically Relevant Unilateral Rat Model of Parkinsonian Akinesia

  1992cited by this paper
• Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease

  1990cited by this paper
• Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism.

  1979cited by this paper
• 6-Hydroxy-dopamine induced degeneration of central monoamine neurons.

  1968cited by this paper

• Molecular and cellular determinants of L-Dopa-induced dyskinesia in Parkinson’s Disease

  2024cites this paper
• Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia

  2023cites this paper
• Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.

  2023cites this paper
• GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases

  2023influential citation
• Attenuation of Vanadium-Induced Neurotoxicity in Rat Hippocampal Slices (In Vitro) and Mice (In Vivo) by ZA-II-05, a Novel NMDA-Receptor Antagonist

  2023cites this paper
• Negative allosteric modulators of NMDA receptors with GluN2B subunit: Alanine‐derived benzoxazolone bioisosteres of 2‐methyl‐3‐benzazepine‐1,7‐diols

  2022cites this paper
• The role of glutamate receptors and their interactions with dopamine and other neurotransmitters in the development of tardive dyskinesia: preclinical and clinical results

  2020cites this paper
• A comprehensive description of GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonists.

  2020cites this paper
• Overview of therapeutic drugs and methods for the treatment of Parkinson's disease.

  2020cites this paper
• Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease

  2019cites this paper
• Glutamatergic mechanisms in l-DOPA-induced dyskinesia and therapeutic implications

  2018cites this paper
• Selegiline increases on time without exacerbation of dyskinesia in 6‐hydroxydopamine‐lesioned rats displaying l‐Dopa‐induced wearing‐off and abnormal involuntary movements

  2018cites this paper
• Design, Synthesis, Pharmacological Evaluation and Docking Studies of GluN2B‐Selective NMDA Receptor Antagonists with a Benzo[7]annulen‐7‐amine Scaffold

  2017cites this paper
• Intrastriatal injection of ionomycin profoundly changes motor response to l-DOPA and its underlying molecular mechanisms.

  2017cites this paper
• Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model

  2016influential citation
• Treatment of the later stages of Parkinson’s disease – pharmacological approaches now and in the future

  2015cites this paper
• NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model.

  2015cites this paper
• NMDARs in neurological diseases: a potential therapeutic target

  2015cites this paper
• Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.

  2015cites this paper
• Targeting glutamatergic synapses in Parkinson's disease.

  2015cites this paper
• Enantiomerically Pure 2-Methyltetrahydro-3-benzazepin-1-ols Selectively Blocking GluN2B Subunit Containing N-Methyl-D-aspartate Receptors.

  2015cites this paper
• Benzo[7]annulene-based GluN2B selective NMDA receptor antagonists: Surprising effect of a nitro group in 2-position.

  2015cites this paper
• NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients

  2015cites this paper
• Therapeutic potential of targeting glutamate receptors in Parkinson’s disease

  2014cites this paper
• GluN2B‐Selective N‐Methyl‐d‐aspartate (NMDA) Receptor Antagonists Derived from 3‐Benzazepines: Synthesis and Pharmacological Evaluation of Benzo[7]annulen‐7‐amines

  2014cites this paper
• Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease

  2014cites this paper
• Unprecedented Therapeutic Potential with a Combination of A2A/NR2B Receptor Antagonists as Observed in the 6-OHDA Lesioned Rat Model of Parkinson's Disease

  2014cites this paper
• Multifunctional approach of L-Dopa induced dyskinesia pathophysiology in Parkinson’s disease : from the striatum to the whole brain

  2014cites this paper
• Investigating group III metabotropic glutamate receptors as novel therapeutic targets in Parkinson's disease and Levodopa-induced dyskinesia

  2014cites this paper
• Glutamate Receptors and Levodopa-Induced Dyskinesia

  2014cites this paper
• Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models

  2014cites this paper
• Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines.

  2014cites this paper
• Expression and phosphorylation of glutamate receptor subunits and CaMKII in a mouse model of Parkinsonism.

  2014cites this paper
• Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments

  2013cites this paper
• GluN2B Antagonism Affects Interneurons and Leads to Immediate and Persistent Changes in Synaptic Plasticity, Oscillations, and Behavior

  2013cites this paper
• Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments

  2013cites this paper
• Glutamate in Parkinson's disease: Role of antiglutamatergic drugs

  2013cites this paper
• Modulation of NMDA receptor at the synapse: promising therapeutic interventions in disorders of the nervous system.

  2013cites this paper
• Diversity in NMDA Receptor Composition

  2013cites this paper
• GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.

  2013cites this paper
• Motor complications in Parkinson's disease: a comprehensive review of emergent management strategies.

  2013cites this paper
• Receptor heteromers in Parkinson's disease and L-DOPA-induced dyskinesia.

  2013cites this paper
• Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease

  2012cites this paper
• Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.

  2012cites this paper
• Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease.

  2012cites this paper
• Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists.

  2011cites this paper
• Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.

  2011cites this paper
• Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function.

  2011cites this paper
• Molecular mechanisms of l-DOPA-induced dyskinesia.

  2011cites this paper
• Design, Synthesis, and Biological Evaluation of 3‐Benzazepin‐1‐ols as NR2B‐Selective NMDA Receptor Antagonists

  2010cites this paper
• Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.

  2010cites this paper
• Pharmacological therapy of Parkinson's disease: current options and new avenues.

  2010cites this paper
• Forelimb dyskinesia mediated by high‐frequency stimulation of the subthalamic nucleus is linked to rapid activation of the NR2B subunit of N‐methyl‐d‐aspartate receptors

  2010influential citation
• New therapeutic strategy for Parkinson's and Alzheimer's disease.

  2010cites this paper
• Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson's disease.

  2010influential citation
• Insights into structure-activity relationships and CNS therapeutic applications of NR2B selective antagonists.

  2010cites this paper
• Calcium‐permeable AMPA receptors are involved in the induction and expression of l‐DOPA‐induced dyskinesia in Parkinson’s disease

  2010cites this paper
• Dopamine Receptors and the Treatment of Parkinson's Disease

  2010cites this paper
• The intranigral injection of tissue plasminogen activator induced blood-brain barrier disruption, inflammatory process and degeneration of the dopaminergic system of the rat.

  2009cites this paper
• Molecular basis of L-DOPA-induced dyskinesia : Studies on striatal signaling

  2009cites this paper
• Allosteric modulators of NR2B‐containing NMDA receptors: molecular mechanisms and therapeutic potential

  2009cites this paper
• Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions.

  2009cites this paper
• Parkinson's disease: emerging pharmacotherapy.

  2008cites this paper
• Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism

  2008cites this paper
• The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development.

  2008cites this paper
• Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on l-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat

  2008cites this paper
• Parkinson's disease: emerging pharmacotherapy

  2008cites this paper
• Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato‐pallidal neurons: relationship to motor response in the 6‐hydroxydopamine model of parkinsonism

  2008cites this paper
• Molecular mechanisms underlying levodopa‐induced dyskinesia

  2008cites this paper
• Molecular pharmacological characterisation of recombinant and native NR2B- and NR3B- containing NMDA receptors

  2008cites this paper
• Potential therapeutic targets for Parkinson's disease

  2008cites this paper
• NMDA receptor subtypes: Structure, function and therapeutics

  2008cites this paper
• Potential therapeutic targets for Parkinson's disease.

  2008cites this paper
• The Nociceptin/Orphanin FQ Receptor Antagonist J-113397 and l-DOPA Additively Attenuate Experimental Parkinsonism through Overinhibition of the Nigrothalamic Pathway

  2007cites this paper
• Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.

  2007cites this paper
• The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-D-aspartate antagonist CP-101 606 in rats and rhesus monkeys

  2007cites this paper
• Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease.

  2007cites this paper
• Comparative analyses of rodent and human brain in ageing and disease using novel NMDAR-2B selective probes

  2007cites this paper
• THE ROLE OF "NMDA" RECEPTOR SUBUNITS IN MOVEMENT DISORDERS INVOLVING BASAL GANGLIA: A BEHAVIOURAL AND NEUROCHEMICAL STUDY

  2007cites this paper
• FUNCTIONAL PROPERTIES OF L-GLUTAMATE REGULATION IN ANESTHETIZED AND FREELY MOVING MICE

  2007cites this paper
• New pharmacologic horizons in the treatment of Parkinson disease

  2006cites this paper
• Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists.

  2006cites this paper
• Changes in Subcellular Distribution and Phosphorylation of GluR1 in Lesioned Striatum of 6-Hydroxydopamine-Lesioned and l-dopa-Treated Rats

  2006cites this paper
• New targets for pharmacological intervention in the glutamatergic synapse.

  2006cites this paper
• A Critical Interaction between NR2B and MAGUK in l-DOPA Induced Dyskinesia

  2006cites this paper
• Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?

  2006cites this paper
• Structural properties of the NMDA receptor and the design of neuroprotective therapies.

  2006cites this paper
• Absolute Oral Bioavailability of Traxoprodil in Cytochrome P450 2D6 Extensive and Poor Metabolisers

  2006cites this paper
• NR2B subtype-selective NMDA receptor antagonists: 2001 – 2004

  2005cites this paper
• Novel pharmacological strategies for motor complications in Parkinson’s disease

  2005cites this paper
• Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP‐treated common marmosets

  2005cites this paper
• Striatal synaptic plasticity: Implications for motor learning and Parkinson's disease

  2005cites this paper
• Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.

  2005cites this paper
• Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

  2005cites this paper
• Nondopaminergic mechanisms in levodopa‐induced dyskinesia

  2005cites this paper